CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.
Category: Novo Nordisk A/S
-
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.
-
Weight Loss Drug Will Be Offered for $499 a Month for Some Patients
Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.
-
Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
-
Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
-
U.S. Unveils Price Limits for 10 Costly or Common Medications
The Biden administration said it would have saved $6 billion had the new prices been in effect last year.
-
U.S. to Announce Prices for First Drugs Picked for Medicare Negotiations
The Biden administration said it would have saved $6 billion had the new prices been in effect last year.
-
How Ozempic Is Transforming a Small Danish Town
In Kalundborg, population under 17,000, Novo Nordisk is making huge investments to increase production of its popular diabetes and weight-loss drugs, Ozempic and Wegovy.
-
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy
Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
-
How Ozempic Turned a 1974 Hit Into an Inescapable Jingle
The diabetes drug has become a phenomenon, and “Oh, oh, oh, Ozempic!” — a takeoff of the Pilot song “Magic” — has played a big part in its story.
-
Investors Shrug off Nvidia’s ‘A.I. Woodstock’
The chipmaker unveiled a new high-speed processor at its developer conference to power an “industrial revolution,” but its sky-high valuation is coming under scrutiny.
-
6 Reasons That It’s Hard to Get Your Wegovy and Other Weight-Loss Prescriptions
An array of obstacles make it difficult for patients to obtain Wegovy or Zepbound. Finding Wegovy is “like winning the lottery,” one nurse practitioner said.